89bio

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.